OmniAb (NASDAQ:OABI) & Repligen (NASDAQ:RGEN) Head-To-Head Survey

Repligen (NASDAQ:RGEN) and OmniAb (NASDAQ:OABI) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, earnings, dividends and profitability.

Earnings and Valuation

This table compares Repligen and OmniAb”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$738.26 million	13.41	$48.89 million	$0.73	240.32
OmniAb	$18.67 million	37.80	-$64.78 million	($0.36)	-13.54

Repligen has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Repligen and OmniAb’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Repligen	5.29%	5.30%	3.79%
OmniAb	-115.12%	-16.59%	-14.82%

Analyst Ratings

This is a summary of current ratings and recommmendations for Repligen and OmniAb, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	0	4	12	2	2.89
OmniAb	1	0	3	0	2.50

Repligen presently has a consensus price target of $175.71, indicating a potential upside of 0.16%. OmniAb has a consensus price target of $11.50, indicating a potential upside of 135.90%. Given OmniAb’s higher possible upside, analysts plainly believe OmniAb is more favorable than Repligen.

Institutional & Insider Ownership

97.6% of Repligen shares are held by institutional investors. Comparatively, 72.1% of OmniAb shares are held by institutional investors. 0.6% of Repligen shares are held by company insiders. Comparatively, 9.8% of OmniAb shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Repligen has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, OmniAb has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.

Summary

Repligen beats OmniAb on 12 of the 15 factors compared between the two stocks.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

About OmniAb

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.